Title : The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol.

Pub. Date : 2016 Apr

PMID : 26248047






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Naloxegol is metabolized by CYP3A, and its properties as a substrate for the P-glycoprotein (PGP) transporter limit its central nervous system (CNS) permeability. naloxegol ATP binding cassette subfamily B member 1 Homo sapiens
2 Naloxegol is metabolized by CYP3A, and its properties as a substrate for the P-glycoprotein (PGP) transporter limit its central nervous system (CNS) permeability. naloxegol ATP binding cassette subfamily B member 1 Homo sapiens
3 Coadministration of quinidine and naloxegol increased naloxegol"s AUC 1.4-fold and Cmax 2.5-fold but did not antagonize morphine-induced miosis, suggesting that PGP inhibition does not increase the CNS penetration of naloxegol. naloxegol ATP binding cassette subfamily B member 1 Homo sapiens
4 Coadministration of quinidine and naloxegol increased naloxegol"s AUC 1.4-fold and Cmax 2.5-fold but did not antagonize morphine-induced miosis, suggesting that PGP inhibition does not increase the CNS penetration of naloxegol. naloxegol ATP binding cassette subfamily B member 1 Homo sapiens
5 Coadministration of quinidine and naloxegol increased naloxegol"s AUC 1.4-fold and Cmax 2.5-fold but did not antagonize morphine-induced miosis, suggesting that PGP inhibition does not increase the CNS penetration of naloxegol. naloxegol ATP binding cassette subfamily B member 1 Homo sapiens